Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 2, 2010, Pages 93-102

  Pattanaik, S ^a   Malhotra, S ^a   Sharma, Y P ^a   Ahluwalia, J ^a   Bhalla, A ^a   Pandhi, P ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cilostazol; Non ST elevation acute coronary syndrome; PAI 1; Platelet aggregation; Triple antiplatelet therapy

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL DISCOMFORT; ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BIOCHEMICAL PARAMETERS; CARDIOVASCULAR EFFECT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART PALPITATION; HUMAN; INSOMNIA; ISCHEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARAMETERS OF MEASUREMENT AND ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTLESSNESS; SIDE EFFECT; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 76749095347     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48093     Document Type: Article

References (33)

1. ACC/AHA 2007. Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in Collaboration with the American College of Emergency Medicine Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Thoracic Surgeons: Endorsed by the American Association of Physicians, the Society for Academic Emergency Medicine. Circulation. 2007; 116: 803-877.
2. Cannon CP, Braunwald E. Unstable angina. In: Libby P, Bonow RO, Mann DL, Zipes DP (eds). Braunwald's Heart Diseases. Philadelphia, PA: Saunders & Co.; 2007. p. 1319-1344.
3. Chen YD, Lu YL, Jin Zn, Yuan F, Lu Sz. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl). 2006; 119: 360-366.
4. De Lemos JA, O'Roukee RA. Unstable angina and Non-ST-Segment ElevationMyocardial Infarction. In: Fuster V, O'Roukee RA,Walsh RA,Wilson PP (eds). Hurst's the Heart. New Delhi:Mc Graw Hill; 2008. p. 1351-1374.
5. Folts JD, Schfer AI, Localzo J, Willerson JT, Muller JE. A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials. J Am Coll Cardiol. 1999; 33: 295-303.
6. Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. Thromb Haemost. 2004; 91: 425-437.
7. Han YL, Su QF, Li Y, Wang SL, Jing QM, Ma YY, Wang ZL,Wang DM, Luan B. Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention. Zhonghua Yi Xue Za Zhi. 2006; 86: 1093-1096.
8. Harvey DW. Unstable angina: Ischemic syndromes. Topol text book of Cardiovascular Medicine. New Delhi: Mc Graw Hill; 2006. p. 251-279.
9. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001; 344: 1608-1621.
10. Hobbs SD, Marshall T, Fegan C, Adam DJ, Bradbury AW. The effect of supervised exercise and cilostazol oncoagulation and fibrinolysis in intermittent claudication: Arandomized controlled trial. J Vasc Surg. 2007; 45: 65-70.
11. Jaremo P, Lindahl TL, Fransson SG, Ritcher A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002; 252: 233-238.
12. Kim JY, Kyounghoon L, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J. 2007; 71: 1867-1872.
13. Kleiman NS, White HD. The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes. Heart. 2005; 91: 1121-1123.
14. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 2000; 49: 633-639.
15. Laborotary techniques. Guidelines on platelet function testing. The British Society for haematology BSH haemostasis and thrombosis task force. J Clin Pathol. 1988; 41: 1322-1330.
16. Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol. 2007; 100: 610-614.
17. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005; 46: 1833-1837.
18. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. DECLARE-Long Study Investigators. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007; 100: 1103-1108.
19. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH,Chun KJ, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus. The DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008; 51: 1181-1187.
20. Liu Y, Shakur Y, Yoshitake M, Kambayashi JiJ. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001; 19: 369-386.
21. Malhotra S, Bhargava VK, Grover A, Pandhi P, Sharma YP. A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial). Int J Clin Pharm Ther. 2001; 39: 110-115.
22. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patientswith acutemyocardial infarction. Circulation. 2004; 109: 3171-3175.
23. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005; 3: 1309-1311.
24. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89: 783-787.
25. Patrono RC, FitzGerald GA, Hirsh J, Gerald R. Platelet-active drugs. The relationship among dose, effectiveness and side effects. The seventh ACCP conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: 234-264.
26. Schrör K. The pharmacology of cilostazol. Diabetes, Obesity and Metabolism. 2002; 4 (Suppl): 14-19.
27. Seegmiller A, Sarode R. Laboratory Evaluation of Platelet Function. Haematol Oncol Clinics NA. 2007; 21: 731-742.
28. Serebruany VN, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005; 45: 246-250.
29. Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins - enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. Pharmacology. 2006; 78: 136-143.
30. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol. 2000; 59: 347-356.
31. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997; 46: 454-457.
32. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004; 109: 3064-3067.
33. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Throm Hemost. 2005; 3: 35-45.